Literature DB >> 2386365

Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein.

J R Knox1, R F Pratt.   

Abstract

A comparison was made of the binding modes of the bacterial cell wall precursor L-lysyl-D-alanyl-D-alanine to the glycopeptide antibiotic vancomycin and to the D-alanyl-D-alanine-cleaving peptidase of Streptomyces sp. strain R61, a model for cell wall-synthesizing enzymes whose X-ray three-dimensional structure is established. In each of the two pairings (vancomycin with peptide and DD-peptidase with peptide), polypeptide backbones were antiparallel, and the antibiotic or enzyme enveloped the peptide substrate from opposite sides. Hydrogen-bonding groups on the substrate which are involved with the DD-peptidase were shown to be different from the ones reported from nuclear magnetic resonance studies to be involved with vancomycin. Because of steric hindrance, the binding of either molecule to the substrate prevents the binding of the other molecule. Binding to the substrate by a D-alanyl-D-alanine-recognizing protein in a manner similar to that used by the DD-peptidase could explain recent observations of vancomycin resistance, in which a new membrane-associated protein has been detected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386365      PMCID: PMC175978          DOI: 10.1128/AAC.34.7.1342

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  D-alanine-D-alanine ligase (ADP) from Salmonella typhimurium. Overproduction, purification, crystallization and preliminary X-ray analysis.

Authors:  J R Knox; H S Liu; C T Walsh; L E Zawadzke
Journal:  J Mol Biol       Date:  1989-01-20       Impact factor: 5.469

2.  Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256.

Authors:  S al-Obeid; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 3.  Molecular basis of the activity of antibiotics of the vancomycin group.

Authors:  D H Williams; J P Waltho
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

4.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO.

Authors:  T A Jones
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

5.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

Review 6.  Penicillin-sensitive enzymes in peptidoglycan biosynthesis.

Authors:  J M Frère; B Joris
Journal:  Crit Rev Microbiol       Date:  1985       Impact factor: 7.624

7.  Two proposed general configurations for bacterial cell wall peptidoglycans shown by space-filling molecular models.

Authors:  E H Oldmixon; S Glauser; M L Higgins
Journal:  Biopolymers       Date:  1974       Impact factor: 2.505

8.  Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine.

Authors:  G M Sheldrick; P G Jones; O Kennard; D H Williams; G A Smith
Journal:  Nature       Date:  1978-01-19       Impact factor: 49.962

9.  A fluorescent ligand for binding studies with glycopeptide antibiotics of the vancomycin class.

Authors:  P H Popieniek; R F Pratt
Journal:  Anal Biochem       Date:  1987-08-15       Impact factor: 3.365

10.  Specificity of combination between mucopeptide precursors and vancomycin or ristocetin.

Authors:  H R Perkins
Journal:  Biochem J       Date:  1969-01       Impact factor: 3.857

View more
  13 in total

1.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  B Moreira; S Boyle-Vavra; B L deJonge; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Peptidoglycan architecture can specify division planes in Staphylococcus aureus.

Authors:  Robert D Turner; Emma C Ratcliffe; Richard Wheeler; Ramin Golestanian; Jamie K Hobbs; Simon J Foster
Journal:  Nat Commun       Date:  2010-06-15       Impact factor: 14.919

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Cationic Branched Polyethylenimine (BPEI) Disables Antibiotic Resistance in Methicillin-Resistant Staphylococcus epidermidis (MRSE).

Authors:  Anh K Lam; Melissa A Hill; Erika L Moen; Jennifer Pusavat; Cassandra L Wouters; Charles V Rice
Journal:  ChemMedChem       Date:  2018-09-25       Impact factor: 3.466

Review 5.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Selective FL quenching or enhancing of diimine ligands by guanine.

Authors:  Srung Smanmoo; Shinya Kawasaki; Pramuan Tangboriboonrat; Takayuki Shibata; Tsutomu Kabashima; Masaaki Kai
Journal:  J Fluoresc       Date:  2013-04-25       Impact factor: 2.217

7.  Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.

Authors:  M C Ramos; M L Grayson; G M Eliopoulos; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex.

Authors:  D M Shlaes; J H Shlaes; S Vincent; L Etter; P D Fey; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  Vancomycin resistance in Enterococcus gallinarum.

Authors:  S Vincent; P Minkler; B Bincziewski; L Etter; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Therapeutic compounds targeting Lipid II for antibacterial purposes.

Authors:  Jakob J Malin; Erik de Leeuw
Journal:  Infect Drug Resist       Date:  2019-08-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.